Session Chair Profile
Ph.D., Chief Scientific Officer, Q2 Solutions
Dr. Hugo leads the global scientific strategy and is responsible for the scientific and medical affairs for the Central Laboratories, Genomic and BioAnalytical/ADME activities. Prior to joining Q2 Solutions, Dr. Hugo was Associated Vice President Chief Scientist, Scientific Affairs Clinical Trials at Laboratory Corporation of America (LabCorp)/Covance, and has held several other prior senior positions such as CSO Clearstone Central Laboratories, Exec. VP R& Caprion and CSO PROCREA BioSciences. Dr. Hugo has more than 25 years of senior scientific leadership experience with extensive management expertise in lab operations, biomarker discovery and validation applied to diagnostics, therapeutic targets and clinical trials. Dr. Hugo has more than 75 scientific publications in internationally renowned journals. He also played an active role He obtained his Ph.D. at McGill University and completed 5 years of post-doctoral fellowship at the Walter Elisa Hall Institute in Australia, and Howard Hughes Medical Institute in Denver.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Undeniably, cancer immunotherapy is one of the most promising areas in cancer research. New clinical trial approaches are under way to advance immune therapies for cancer. We will hear from both industry and medical representatives about their novel and innovative programs, which have the goal of expediting immunotherapy cancer treatments and delivering better patient outcomes.